Plain-English translation of NCT07449325 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This early-stage trial is testing a device called the A-FLUX Coronary Sinus Reducer, which is designed to help people with chest pain caused by coronary microvascular dysfunction—a condition where the smallest blood vessels in the heart aren't working properly. The device is placed in a vein near the heart to improve blood flow and reduce symptoms. This study will look at whether the device is safe and works well for people whose chest pain hasn't gotten better with medication.
Many people experience chest pain caused by problems in the heart's smallest blood vessels, and standard medications don't always relieve their symptoms. This trial exists to see if this new device offers a treatment option for those patients.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will undergo the device implantation procedure, which involves placing the A-FLUX Coronary Sinus Reducer into a vein near your heart through a catheter (a thin tube). The research team will monitor your heart function before, during, and after the procedure with imaging and pressure measurements. You will then complete follow-up visits as scheduled by the study team to assess your symptoms and the device's safety and performance over time.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
United States